Young child with Doctor


Latest press releases

AstraZeneca appoints Pam Cheng as Executive Vice President, Operations and IT
16 June 2015
AstraZeneca reveals findings of archaeological dig as build gets underway at Cambridge Biomedical Campus
11 June 2015
New real-world data analysis finds no evidence of increased risk of hospitalisation for heart failure with saxagliptin compared with sitagliptin
8 June 2015
AstraZeneca presents new positive phase III data on triple therapy approach with dapagliflozin, saxagliptin and metformin for the treatment of type 2 diabetes
6 June 2015
AstraZeneca to present data demonstrating progress of its comprehensive diabetes portfolio at the American Diabetes Association 75th Scientific Sessions
3 June 2015
AstraZeneca updates on immuno-oncology combinations development programme at ASCO 2015
2 June 2015
AstraZeneca and MedImmune present positive immuno-oncology combination data at ASCO 2015
30 May 2015
AstraZeneca and Lilly to collaborate on Immuno-oncology combination clinical trial in solid tumours
29 May 2015
AstraZeneca provides update on brodalumab development programme
22 May 2015
AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden, to support accelerating biologics portfolio
18 May 2015
AstraZeneca to update on progress with immuno-oncology pipeline and combination treatments at ASCO 2015
13 May 2015
AstraZeneca and Abbott to develop companion diagnostic tests for tralokinumab in severe asthma
13 May 2015

Fast facts

AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives.

Our primary focus is on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). We are also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas.

First quarter results 2015

24 April 2015

The following slides are available to download for the media.

Download presentation (PDF 1014kb)

Photo and video library

AstraZeneca in Cambridge

Broadcast video

Board and management



Operations and Manufacturing

Research & Development

Sign up to email alerts

Your email address will only be used to provide you with services from AstraZeneca that you requested. You can opt out for email subscriptions any time. Your personal information will not be provided to any third party without your permission.